This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
511 |
4. Check minimum number of events
Min. number of events
3
|
511 |
5. Include endpointsNone |
511 |
6. Filter based on genotype QC (FinnGen only) |
487 |
Control definitions (FinnGen only)
Control exclude
RX_L04AB
Extra metadata
First used in FinnGen datafreeze
DF4
Similar endpoints
↥List of similar endpoints to
Certolizumab pegol
based on the number of shared cases.
Similar with more cases:
- Tumor necrosis factor alpha inhibitors
- Biological medication for rheuma
- ILD medications: immunosuppressive drugs
- ILD medications
- Any reimbursement code in KELA
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 487 | 379 | 108 |
| Unadjusted period prevalence (%) | 0.13 | 0.15 | 0.05 |
| Median age at first event (years) | 42.37 | 40.08 | 50.39 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L04AB05 – Certolizumab pegol
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).